Regine Schneider-Stock

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7411678/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Gene Signature Derived from the Loss of CDKN1A (p21) Is Associated with CMS4 Colorectal Cancer. Cancers, 2022, 14, 136.	3.7	3
2	Multiphoton Microscopy Reveals DAPK1-Dependent Extracellular Matrix Remodeling in a Chorioallantoic Membrane (CAM) Model. Cancers, 2022, 14, 2364.	3.7	5
3	Abstract 3368: Biomarkers of precancerous colorectal cancer stages identified by transcriptome profiling. Cancer Research, 2022, 82, 3368-3368.	0.9	0
4	ATF2 loss promotes tumor invasion in colorectal cancer cells via upregulation of cancer driver TROP2. Cellular and Molecular Life Sciences, 2022, 79, .	5.4	12
5	miR-138-5p induces aggressive traits by targeting Trp53 expression in murine melanoma cells, and correlates with poor prognosis of melanoma patients. Neoplasia, 2021, 23, 823-834.	5.3	7
6	Tetraspanin 5 (TSPAN5), a Novel Gatekeeper of the Tumor Suppressor DLC1 and Myocardin-Related Transcription Factors (MRTFs), Controls HCC Growth and Senescence. Cancers, 2021, 13, 5373.	3.7	6
7	Novel Criteria for Intratumoral Budding with Prognostic Relevance for Colon Cancer and Its Histological Subtypes. International Journal of Molecular Sciences, 2021, 22, 13108.	4.1	5
8	The CAM Assay as an Alternative In Vivo Model for Drug Testing. Handbook of Experimental Pharmacology, 2020, 265, 303-323.	1.8	27
9	New Oleoyl Hybrids of Natural Antioxidants: Synthesis and In Vitro Evaluation as Inducers of Apoptosis in Colorectal Cancer Cells. Antioxidants, 2020, 9, 1077.	5.1	14
10	EMT transcription factor ZEB1 alters the epigenetic landscape of colorectal cancer cells. Cell Death and Disease, 2020, 11, 147.	6.3	58
11	Loss of enhancer of zeste homologue 2 (EZH2) at tumor invasion front is correlated with higher aggressiveness in colorectal cancer cells. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2227-2240.	2.5	27
12	Epigenetic Regulation of p21cip1/waf1 in Human Cancer. Cancers, 2019, 11, 1343.	3.7	22
13	Gene expression and promoter methylation of angiogenic and lymphangiogenic factors as prognostic markers in melanoma. Molecular Oncology, 2019, 13, 1433-1449.	4.6	20
14	Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells. Cell Death and Disease, 2019, 10, 379.	6.3	48
15	DNA methylation and chromatin modifiers in colorectal cancer. Molecular Aspects of Medicine, 2019, 69, 73-92.	6.4	34
16	DAPK1 loss triggers tumor invasion in colorectal tumor cells. Cell Death and Disease, 2019, 10, 895.	6.3	41
17	The activating transcription factor 2: an influencer of cancer progression. Mutagenesis, 2019, 34, 375-389.	2.6	39
18	Carboraneâ€Based Analogues of 5â€Lipoxygenase Inhibitors Coâ€inhibit Heat Shock Protein 90 in HCT116 Cells. ChemMedChem, 2019, 14, 255-261.	3.2	18

#	Article	IF	CITATIONS
19	Deep hypothermic circulatory arrest or tepid regional cerebral perfusion: impact on haemodynamics and myocardial integrity in a randomized experimental trial. Interactive Cardiovascular and Thoracic Surgery, 2018, 26, 667-672.	1.1	4
20	Generation and characterization of hepatocellular carcinoma cell lines with enhanced cancer stem cell potential. Journal of Cellular and Molecular Medicine, 2018, 22, 6238-6248.	3.6	27
21	Cytoplasmic p21 Mediates 5-Fluorouracil Resistance by Inhibiting Pro-Apoptotic Chk2. Cancers, 2018, 10, 373.	3.7	25
22	Identification of miRNA-mRNA Modules in Colorectal Cancer Using Rough Hypercuboid Based Supervised Clustering. Scientific Reports, 2017, 7, 42809.	3.3	13
23	Synthesis of Novel Hybrids of Thymoquinone and Artemisinin with High Activity and Selectivity Against Colon Cancer. ChemMedChem, 2017, 12, 226-234.	3.2	67
24	SIRT1 regulates Mxd1 during malignant melanoma progression. Oncotarget, 2017, 8, 114540-114553.	1.8	12
25	Uptake, delivery, and anticancer activity ofÂthymoquinone nanoparticles in breast cancer cells. Journal of Nanoparticle Research, 2016, 18, 1.	1.9	22
26	Biofabrication of 3D Alginate-Based Hydrogel for Cancer Research: Comparison of Cell Spreading, Viability, and Adhesion Characteristics of Colorectal HCT116 Tumor Cells. Tissue Engineering - Part C: Methods, 2016, 22, 708-715.	2.1	54
27	In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers. Nuclear Medicine and Biology, 2016, 43, 27-34.	0.6	4
28	HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2016, 7, 433-445.	1.8	12
29	Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory bowel disease (Review). International Journal of Oncology, 2015, 47, 5-15.	3.3	20
30	miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis. Inflammatory Bowel Diseases, 2015, 21, 2039-2051.	1.9	53
31	Gallotannin is a DNA damaging compound that induces senescence independently of p53 and p21 in human colon cancer cells. Molecular Carcinogenesis, 2015, 54, 1037-1050.	2.7	12
32	Defective Autophagosome Formation in p53-Null Colorectal Cancer Reinforces Crocin-Induced Apoptosis. International Journal of Molecular Sciences, 2015, 16, 1544-1561.	4.1	66
33	Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma. Cancer Letters, 2015, 367, 147-156.	7.2	9
34	Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients. Dermatology, 2015, 231, 127-133.	2.1	10
35	Absolute quantification of DcR3 and <scp>GDF</scp> 15 from human serum by <scp>LC</scp> â€ <scp>ESI MS</scp> . Journal of Cellular and Molecular Medicine, 2015, 19, 1656-1671.	3.6	7
36	DAPK loss in colon cancer tumor buds: implications for migration capacity of disseminating tumor cells. Oncotarget, 2015, 6, 36774-36788.	1.8	14

#	Article	IF	CITATIONS
37	Thymoquinone: fifty years of success in the battle against cancer models. Drug Discovery Today, 2014, 19, 18-30.	6.4	176
38	DAPK and cytoskeleton-associated functions. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 329-338.	4.9	27
39	Transcription control of DAPK. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 298-305.	4.9	29
40	Death-associated kinase (DAPK): a cancer "gene chameleon― Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 285-285.	4.9	13
41	DAPK-HSF1 interaction as a new positive feedback loop for TNF-induced apoptosis in colorectal cancer cells. Journal of Cell Science, 2014, 127, 5273-87.	2.0	20
42	Thymoquinone-induced conformational changes of PAK1 interrupt prosurvival MEK-ERK signaling in colorectal cancer. Molecular Cancer, 2014, 13, 201.	19.2	50
43	Identification of DAPK as a scaffold protein for the LIMK/cofilin complex in TNF-induced apoptosis. International Journal of Biochemistry and Cell Biology, 2013, 45, 1720-1729.	2.8	22
44	A novel complex KIT mutation in a gastrointestinal stromal tumor of the vermiform appendix. Human Pathology, 2013, 44, 651-655.	2.0	4
45	ATF2 knockdown reinforces oxidative stressâ€induced apoptosis in TE7 cancer cells. Journal of Cellular and Molecular Medicine, 2013, 17, 976-988.	3.6	19
46	Prognostic value of O-6-methylguanine-DNA methyltransferase loss in salivary gland carcinomas. Head and Neck, 2013, 36, n/a-n/a.	2.0	3
47	Thymoquinone induces apoptosis in malignant T-cells via generation of ROS. Frontiers in Bioscience - Elite, 2013, E5, 706-719.	1.8	39
48	Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review. Current Pharmaceutical Biotechnology, 2012, 13, 2248-2258.	1.6	8
49	DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 1300-1315.	4.9	68
50	The anticancer effect of saffron in two p53 isogenic colorectal cancer cell lines. BMC Complementary and Alternative Medicine, 2012, 12, 69.	3.7	55
51	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
52	Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Letters, 2011, 312, 43-54.	7.2	125
53	Cutting edge: Chk1 directs senescence and mitotic catastrophe in recovery from G2 checkpoint arrest. Journal of Cellular and Molecular Medicine, 2011, 15, 1528-1541.	3.6	26
54	Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). , 2011, 312, 43-43.		1

#	Article	IF	CITATIONS
55	Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 183-195.	4.9	240
56	Aberrant methylation of DAPK in long-standing ulcerative colitis and ulcerative colitis-associated carcinoma. Pathology Research and Practice, 2010, 206, 616-624.	2.3	37
57	The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cellular Oncology, 2010, 32, 285-300.	1.9	38
58	Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. Journal of Cellular and Molecular Medicine, 2008, 12, 330-342.	3.6	137
59	Thymoquinone Triggers Inactivation of the Stress Response Pathway Sensor <i>CHEK1</i> and Contributes to Apoptosis in Colorectal Cancer Cells. Cancer Research, 2008, 68, 5609-5618.	0.9	145
60	Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biology and Therapy, 2007, 6, 160-169.	3.4	169
61	Histone deacetylase inhibitors: Signalling towards p21cip1/waf1. International Journal of Biochemistry and Cell Biology, 2007, 39, 1367-1374.	2.8	245
62	DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Letters, 2006, 240, 69-75.	7.2	62
63	Methyltransferases in apoptosis and cancer. Signal Transduction, 2005, 5, 169-176.	0.4	1
64	DAP-kinase—Protector or enemy in apoptotic cell death. International Journal of Biochemistry and Cell Biology, 2005, 37, 1763-1767.	2.8	22
65	Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clinical Cancer Research, 2005, 11, 638-45.	7.0	77
66	Selective Loss of Codon 72 Proline p53 and Frequent Mutational Inactivation of the Retained Arginine Allele in Colorectal Cancer. Neoplasia, 2004, 6, 529-535.	5.3	43
67	Retention of the Arginine Allele in Codon 72 of the p53 Gene Correlates with Poor Apoptosis in Head and Neck Cancer. American Journal of Pathology, 2004, 164, 1233-1241.	3.8	58
68	Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. International Journal of Oncology, 2004, 25, 857-66.	3.3	89
69	Different mRNA Expression Profile During Tumor Progressionin a Well-differentiated Liposarcoma – A Microdissection Approach. Pathology Research and Practice, 2003, 199, 445-450.	2.3	6
70	Elevated telomerase activity,c-MYC-, andhTERTmRNA expression: association with tumour progression in malignant lipomatous tumours. Journal of Pathology, 2003, 199, 517-525.	4.5	37
71	Gastrointestinal Stromal Tumors with Internal Tandem Duplications in 3' End of KIT Juxtamembrane Domain Occur Predominantly in Stomach and Generally Seem to Have a Favorable Course. Modern Pathology, 2003, 16, 1257-1264.	5.5	104
72	KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin1 1The opinions and assertions contained herein are the expressed views of the authors and are not to be construed as official or reflecting the views of the Departments of the Army or Defense Human Pathology, 2003, 34, 1306-1312.	2.0	87

#	Article	IF	CITATIONS
73	High Prognostic Value of p16 ^{<i>INK4</i>} Alterations in Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 2003, 21, 1688-1697.	1.6	145
74	Differences in loss of p16INK4 protein expression by promoter methylation between left- and right-sided primary colorectal carcinomas. International Journal of Oncology, 2003, 23, 1009-13.	3.3	9
75	Significance of loss of heterozygosity of theRB1gene during tumour progression in well-differentiated liposarcomas. Journal of Pathology, 2002, 197, 654-660.	4.5	23
76	Analysis of human telomerase reverse transcriptase mRNA (hTERT) expression in myxoid liposarcomas using LightCycler real-time quantitative reverse transcriptase-polymerase chain reaction. Electrophoresis, 2001, 22, 1098-1101.	2.4	17
77	Gliomatosis cerebri: post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide. Journal of Neuro-Oncology, 2001, 55, 11-17.	2.9	17
78	High telomerase activity and high HTRT mRNA expression differentiate pure myxoid and myxoid/round-cell liposarcomas. International Journal of Cancer, 2000, 89, 63-68.	5.1	26
79	Mdm2 Gene Amplification in Gastric Cancer Correlation with Expression of Mdm2 Protein and p53 Alterations. Modern Pathology, 2000, 13, 621-626.	5.5	65
80	Telomeric lengths and telomerase activity in liposarcomas. Molecular Carcinogenesis, 1999, 24, 144-151.	2.7	20
81	On telomere shortening in soft-tissue tumors. Journal of Cancer Research and Clinical Oncology, 1998, 124, 165-171.	2.5	31
82	Improved detection of P53 mutations in soft tissue tumors using new gel composition for automated nonradioactive analysis of single-strand conformation polymorphism. Electrophoresis, 1997, 18, 2849-2851.	2.4	15
83	New splicing mutation in exon 5–6 of the p53-tumor suppressor gene in a malignant schwannoma. Human Mutation, 1997, 9, 91-94.	2.5	6
84	Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas. Journal of Cancer Research and Clinical Oncology, 1996, 122, 161-165.	2.5	15